Caribou Biosciences (CRBU) Change in Accured Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Change in Accured Expenses data on file, last reported at -$2.6 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 14.67% year-over-year to -$2.6 million in Q1 2026; TTM through Mar 2026 was -$5.9 million, a 575.75% decrease from a year earlier, with the FY2025 full-year figure at -$6.3 million, down 397.09% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$2.6 million, up from -$2.8 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for CRBU reached as high as $5.0 million in Q2 2024 and fell as low as -$4.1 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged $49647.1 across 5 years, with a median of -$7000.0 in 2022.
• On a YoY basis, Change in Accured Expenses climbed as much as 53057.14% in 2023 and fell as far as 51625.0% in 2023.
• Year by year, Change in Accured Expenses stood at $1.0 million in 2022, then jumped by 177.3% to $2.9 million in 2023, then tumbled by 176.23% to -$2.2 million in 2024, then declined by 27.59% to -$2.8 million in 2025, then rose by 6.04% to -$2.6 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$2.6 million in Q1 2026, -$2.8 million in Q4 2025, and -$1.1 million in Q3 2025.